Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: International consensus statement

European Journal of Neurology

Volumn 17, Issue SUPPL. 2, 2010, Pages 57-73

  Olver, J ^a   Esquenazi, A ^b   Fung, V S C ^c   Singer, B J ^d   Ward, A B ^e  

^a Epworth Healthcare ^*  (Australia)

^b MossRehab Gait and Motion Analysis Laboratory   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e HAYWOOD HOSPITAL   (United Kingdom)

Author keywords

adult; Botulinum toxin; hypertonicity; lower limb; outcomes assessment; spasticity

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

AFTERCARE; BRACE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSENSUS; CONSTIPATION; CONSULTATION; CONTRACTURE; DEEP VEIN THROMBOSIS; DYSESTHESIA; DYSTONIA; ELECTROSTIMULATION; FLU LIKE SYNDROME; HUMAN; LEG; LIMB DISEASE; MOTOR DYSFUNCTION; MUSCLE CONTRACTURE; MUSCLE HYPERTONIA; MUSCLE SPASM; MUSCLE STRETCHING; MUSCLE TONE; MUSCLE WEAKNESS; NEURALGIA; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PATIENT CARE; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; RANGE OF MOTION; REVIEW; SEIZURE; SPASTICITY; TENDINITIS; TREATMENT DURATION;

ADULT; BOTULINUM TOXINS, TYPE A; DIAGNOSIS, DIFFERENTIAL; DRUG MONITORING; DYSTONIC DISORDERS; ELECTRIC STIMULATION THERAPY; HUMANS; INTERNATIONALITY; LEG; MOVEMENT DISORDERS; NEUROMUSCULAR AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); PARAPARESIS, SPASTIC; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; PHYSICAL THERAPY MODALITIES;

EID: 77954708882     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03128.x     Document Type: Review

References (84)

1. American Academy of Neurology (AAN). AAN classification of evidence for therapeutic intervention. Available online: http://www.aan.com/go/practice/ guidelines.
2. Esquenazi A, Novak I, Sheean G, Singer BJ, Ward A. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments. Eur J Neurol 2010 17 (Suppl. 2): 3 10.
3. World Health Organization. International Classification of Functioning, Disability and Health (ICF). 2001. Available online: http://www.who.int/ classifications/icf/en/.
4. Steiner WA, Ryser L, Huber E, Uebelhart D, Aeschlimann A, Stucki G. Use of the ICF model as a clinical problem-solving tool in physical therapy and rehabilitation medicine. Phys Ther 2002 82 : 1098 1107.
5. Dodds TA, Martin DP, Stolov WC, Deyo RA. A validation of the functional independence measurement and its performance among rehabilitation inpatients. Arch Phys Med Rehabil 1993 74 : 531 536.
6. Shah SN, Hornyak J, Urquhart AG. Flexion contracture after total knee arthroplasty in a patient with Parkinson's disease: successful treatment with botulinum toxin type A. J Arthroplasty 2005 20 : 1078 1080.
7. Fock J, Galea MP, Stillman BC, Rawicki B, Clark M. Functional outcome following botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury. Brain Inj 2004 18 : 57 63.
8. Caty GD, Detrembleur C, Bleyenheuft C, Deltombe T, Lejeune TM. Effect of simultaneous botulinum toxin injections into several muscles on impairment, activity, participation, and quality of life among stroke patients presenting with a stiff knee gait. Stroke 2008 39 : 2803 2808.
9. McHorney CA, Ware JE Jr., Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993 31 : 247 263.
10. Bouffioulx E, Arnould C, Thonnard JL. SATIS-Stroke: a satisfaction measure of activities and participation in the actual environment experienced by patients with chronic stroke. J Rehabil Med 2008 40 : 836 843.
11. Wade DT. Goal setting in rehabilitation: an overview of what, why and how. Clin Rehabil 2009 23 : 291 295.
12. Turner-Stokes L. Goal attainment scaling (GAS) in rehabilitation: a practical guide. Clin Rehabil 2009 23 : 362 370.
13. Mackay G, Sommerville W. Reflections on goal attainment scaling. Educ Res 1996 2 : 161 171.
14. Cusick A, McIntyre S, Novak I, Lannin N, Lowe K. A comparison of goal attainment scaling and the Canadian Occupational Performance Measure for paediatric rehabilitation research. Pediatr Rehabil 2006 9 : 149 157.
15. Tennant A. Goal attainment scaling: current methodological challenges. Disabil Rehabil 2007 29 : 1583 1588.
16. Yip AM, Gorman MC, Stadnyk K, Mills WG, MacPherson KM, Rockwood K. A standardized menu for Goal Attainment Scaling in the care of frail elders. Gerontologist 1998 38 : 735 742.
17. Ashworth B. Preliminary trial of carisoprodal in multiple sclerosis. Practitioner 1964 192 : 540 542.
18. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987 67 : 206 207.
19. Burbaud P, Wiart L, Dubos JL, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996 61 : 265 269.
20. ®) in the treatment of spasytic equinovarus deformity after stroke. Cerebrovasc Dis 2003 15 : 289 300.
21. Reiter F, Danni M, Lagalla G, Ceravolo G, Provinciali L. Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Arch Phys Med Rehabil 1998 79 : 532 535.
22. Johnson CA, Burridge JH, Strike PW, Wood DE, Swain ID. The effect of combined use of botulinum toxin type A and functional electric stimulation in the treatment of spastic drop foot after stroke: a preliminary investigation. Arch Phys Med Rehabil 2004 85 : 902 909.
23. ®) for the treatment of spastic foot. Neurol Sci 2005 26 : 26 31.
24. Rousseaux M, Compère S, Launay MJ, Kozlowski O. Variability and predictability of functional efficacy of botulinum toxin injection in leg spastic muscles. J Neurol Sci 2005 232 : 51 57.
25. Cioni M, Esquenazi A, Hirai B. Effects of botulinum toxin-A on gait velocity, step length, and base of support of patients with dynamic equinovarus foot. Am J Phys Med Rehabil 2006 85 : 600 606.
26. Bayram S, Sivrioglu K, Karli N, Ozcan O. Low-dose botulinum toxin with short-term electrical stimulation in poststroke spastic drop foot: a preliminary study. Am J Phys Med Rehabil 2006 85 : 75 81.
27. Farina S, Migliorini C, Gandolfi M, et al. Combined effects of botulinum toxin and casting treatments on lower limb spasticity after stroke. Funct Neurol 2008 23 : 87 91.
28. Stoquart GG, Detrembleur C, Palumbo S, Deltombe T, Lejeune TM. Effect of botulinum toxin injection in the rectus femoris on stiff-knee gait in people with stroke: a prospective observational study. Arch Phys Med Rehabil 2008 89 : 56 61.
29. Robertson JV, Pradon D, Bensmail D, Fermanian C, Bussel B, Roche N. Relevance of botulinum toxin injection and nerve block of rectus femoris to kinematic and functional parameters of stiff knee gait in hemiplegic adults. Gait Posture 2009 29 : 108 112.
30. Esquenazi A, Mayer N, Garreta R. Influence of botulinum toxin type A treatment of elbow flexor spasticity on hemiparetic gait. Am J Phys Med Rehabil 2008 87 : 305 310.
31. Richardson D, Sheean G, Werring D, et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000 69 : 499 506.
32. ®) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double-blind, placebo-controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000 68 : 707 712.
33. Opara J, Hordyńska E, Swoboda A. Effectiveness of botulinum toxin A in the treatment of spasticity of the lower extremities in adults - preliminary report. Ortop Traumatol Rehabil 2007 9 : 277 285.
34. Kirazli Y, On AY, Kismali B, Aksit R. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil 1998 77 : 510 515.
35. Dunne JW, Heye N, Dunne SL. Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry 1995 58 : 232 235.
36. Pierson SH, Katz DI, Tarsy D. Botulinum Toxin A in the treatment of spasticity: functional implications and patient selection. Arch Phys Med Rehabil 1996 77 : 717 721.
37. Mayer N, Esquenazi A. Muscle overactivity and movement dysfunction in the upper motoneuron syndrome. Phys Med Rehabil Clin N Am 2003 14 : 855 883.
38. Snow BJ, Tsui JKC, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double blind study. Ann Neurol 1990 28 : 512 515.
39. Ward AB. A summary of spasticity management - a treatment algorithm. Eur J Neurol 2002 9 Suppl. 1 : 48 52.
40. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995 45 : 712 717.
41. Das TK, Park DM. Effect of treatment with botulinum toxin on spasticity. Postgrad Med J 1989 65 : 208 210.
42. Hesse S, Krajnik J, Luecke D, Jahnke MT, Gregoric M, Mauritz KH. Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke 1996 27 : 455 460.
43. Verplancke D, Snape S, Salisbury CF, Jones PW, Ward AB. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil 2005 19 : 117 125.
44. Suputtitada A. Local botulinum toxin type A injections in the treatment of spastic toes. Am J Phys Med Rehabil 2002 81 : 770 775.
45. Lim ECH, Ong BKC, Seet RCS. Botulinum toxin-A injections for spastic toe clawing. Parkinsonism Relat Disord 2006 12 : 43 47.
46. ® (BT-A) purified neurotoxin complex relative to other botulinum neurotoxin preparations. Eur J Neurol 1999 6 : 53 510.
47. Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan S, Simpson DM. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil 2009 90 : 9 16.
48. Mayer NH, Whyte J, Wannstedt G, Ellis CA. Comparative impact of 2 botulinum toxin injection techniques for elbow flexor hypertonia. Arch Phys Med Rehabil 2008 89 : 982 987.
49. Haig AJ, Goodmurphy CW, Harris AR, Ruiz AP, Etemad J. The accuracy of needle placement in lower-limb muscles: a blinded study. Arch Phys Med Rehabil 2003 84 : 877 882.
50. Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum type A in adult spasticity. J Rehabil M 2009 41 : 13 25.
51. Hatherway CG, Deng C. Immunogenicity of the neurotoxins of Clostridium botulinum. In : Jankovic J, Hallett M eds. Therapy with Botulinum Toxin.
52. Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in Adults: Management Using Botulinum Toxin. National Guidelines.
53. Mayer N, Brashear A, eds. The Upper Motor Neuron Syndrome and Muscle Overactivity including Spasticity and the Role of Botulinum Toxin. We Move. 2008. ASIN: B001R2MS7I
54. Varghese-Kroll E, Elovic EP. Contralateral weakness and fatigue after high-dose botulinum toxin injection for management of poststroke spasticity. Am J Phys Med Rehabil 2009 88 : 495 499.
55. Hambleton P, Pickett AM, Shone CC. Botulinum toxin: from menace to medicine. In : Ward AB, Barnes MP eds. Clinical Uses of Botulinum Toxins.
56. Esquenazi A. Assessment of acquired brain injury related muscle overactivity and spasticity with dynamic poly-EMG and motion analysis for lower extremity chemodenervation with botulinum toxin. In : Elovic EP, Brashear A eds. Spasticity: Diagnosis and Management.
57. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum toxin B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992 359 : 832 835.
58. Comella JX, Molgo J, Faille L. Sprouting of mammalian motor nerve terminals induced by in vivo injection of botulinum type-D toxin and the functional recovery of paralysed neuromuscular junctions. Neurosci Lett 1993 153 : 61 64.
59. de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999 96 : 3200 3205.
60. Giovannelli M, Borriello G, Castri P, et al. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 2007 21 : 331 337.
61. Marciniak C, Rader L, Gagnon C. The use of botulinum toxin for spasticity after spinal cord injury. Am J Phys Med Rehabil 2008 87 : 312 317.
62. Rousseaux M, Launay MJ, Kozlowski O, Daveluy W. Botulinum toxin injection in patients with hereditary spastic paraparesis. Eur J Neurol 2007 14 : 206 212.
63. Bergfeldt U, Borg K, Kullander K, Julin P. Focal spasticity therapy with botulinum toxin: effects on function, activities of daily living and pain in 100 adult patients. J Rehabil M 2006 38 : 166 171.
64. Wissel J, Müller J, Heinen F, et al. [Safety and tolerance of single-dose botulinum toxin Type A treatment in 204 patients with spasticity and localized associated symptoms. Austrian and German botulinum toxin A spasticity study group]. Wien Klin Wochenschr 1999 111 : 837 842.
65. Baricich A, Carda S, Bertoni M, Maderna L, Cisari C. A single-blinded, randomized pilot study of botulinum toxin type A combined with non-pharmacological treatment for spastic foot. J Rehabil M 2008 40 : 870 872.
66. Hesse S, Jahnke MT, Luecke D, Mauritz KH. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 1995 201 : 37 40.
67. Eleopra R, Tugnoli V, De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans. Mov Disord 1997 12 : 89 94.
68. Brin MF, Jankovic J, Comella C, et al. Treatment of dystonia using Botulinum toxin. In : Kurlan R ed. Treatment of Movement Disorders.
69. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987 37 : 616 623.
70. Frueh BR, Felt DP, Wojno TH, Musch DC. Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch Ophthal 1984 102 : 1464 1468.
71. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986 2 : 245 247.
72. Schneider SA, Edwards MJ, Grill SE, et al. Adult-onset primary lower limb dystonia. Mov Disord 2006 21 : 767 771.
73. Duarte J, Sempere AP, Coria F, et al. Isolated idiopathic adult-onset foot dystonia and treatment with botulinum toxin. J Neurol 1995 242 : 114 115.
74. Gurevich T, Peretz C, Moore O, Weizmann N, Giladi N. The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study. Mov Disord 2007 22 : 880 883.
75. Wieler M, Camicioli R, Jones CA, Martin WR. Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology 2005 65 : 626 628.
76. Fernandez HH, Lannon MC, Trieschmann ME, Friedman JH. Botulinum toxin type B for gait freezing in Parkinson's disease. Med Sci Monit 2004 10 : CR282 CR284.
77. Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. 'Off' painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 1995 10 : 333 336.
78. Mahant N, Cordato DJ, Fung VS. Focal myoclonus-dystonia of the leg secondary to a lesion of the posterolateral putamen: clinical and neurophysiological features. Mov Disord 2003 18 : 452 455.
79. Kowacs PA, Teive HA, Piovesan EJ, Zavala JA, Werneck LC. Botulinum-A toxin in the treatment of painful post-stroke nocturnal paroxysmal dystonia triggered by periodic limb movements of sleep: case report. Arq Neuropsiquiatr 2006 64 : 1027 1029.
80. Kurtis MM, Floyd AG, Yu QP, Pullman SL. High doses of botulinum toxin effectively treat disabling up-going toe. J Neurol Sci 2008 264 : 118 120.
81. Esquenazi A. Botulinum Neurotoxin in Muscle Overactivity. J Head Trauma Rehabil 2005 20 : 563 567.
82. Nauman M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of toxin type A following long-term use. Eur J Neurol 2006 13 (Suppl. 4 35 40.
83. Turkel CC, Bowen B, Liu J, Brin MF. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil 2006 87 : 786 792.
84. Yablon SA, Brashear A, Gordon MF, et al. Formation of neutralising antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther 2007 29 : 683 690.